May 2020 Br J Cardiol 2020;27:47–8 doi:10.5837/bjc.2020.015
Anthony Rees, BJC Staff
Professor Anthony Rees writes about the hurdles to overcome in COVID-19 vaccine development At the time of writing there are more than 120 proposed vaccine approaches, seven of which are in clinical trial (Phase 1 or Phase1/2) and 70 or so in preclinical evaluation.1 Of those in clinical studies: two encode vectors where the surface S-protein of COVID-19 is incorporated into a non-replicating chimpanzee adenovirus vector (China and UK) two use a conventional inactivated whole virus (both China) two employ a messenger RNA vector encoding the S-protein (China and USA) one is a DNA vaccine (USA). The time frames for each of these clinical tria
February 2015 Br J Cardiol 2015;22:25 Online First
Dr Mike Clark
Author: Rees AR Publisher: Oxford University Press, 2014 ISBN: 978-0-19-964657-9, Price: £44.99 Editor”s introduction The field of immunology cuts across all disciplines in biology, including cancer, heart disease, organ transplantation, and many others. Most human diseases can be traced to an immunologic or inflammatory component. While researchers strive to understand the immuno-pathogenesis of vascular disease and to develop a vaccine to conquer atherosclerosis, we may need to broaden our own horizons and revisit the basic principles underlying how the human immune system works. Where better to start than the antibody. The BJC is th
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits